Comparative Effectiveness and Safety of Labetalol Versus Nifedipine for Treatment of Chronic Hypertension During Pregnancy
Authors' conclusion
This study suggests that labetalol and nifedipine have similar effectiveness and safety in treating chronic hypertension during pregnancy.
Study context
- Population
- Pregnant individuals with chronic hypertension and their infants, U.S. Merative MarketScan Commercial Database (2007–2022)pregnant individuals with chronic hypertension who initiated labetalol or nifedipine in pregnancy
- Participants
- 6,724 individuals
- Exposure
- New users of labetalol with new users of nifedipine
- Labetaloln = 5,504
- Nifedipinen = 1,220reference
- Outcome
- Effectiveness outcome: composite of severe preeclampsia/eclampsia, medically indicated preterm birth, placental abruption, or stillbirth
Methodological detailsnew users, insurance claims database, stabilized inverse probability of treatment weights
- New users
- Insurance claims database
- Stabilized inverse probability of treatment weights
Main finding
As reported in the abstract
Adjusted relative risk (95% CI)
Labetalolvs nifedipine
1.03(0.96–1.11)
Adjusted RD, per 100 births (95% CI)
Between labetalol and nifedipine
1.35(−1.76 to 4.45)
Observational data: associations, not effects.
Safety
| Outcome | Labetalol | Nifedipine | Adjusted RR (95% CI) | |
|---|---|---|---|---|
| Small for gestational age (safety outcome) | 13% | 12% | 0.98 (0.82–1.16) | |
| 0.512Adjusted relative risk (log scale) |
| Outcome | Adjusted RD (per 100 births) (95% CI) | |
|---|---|---|
| Small for gestational age (safety outcome) | −0.26 (−2.33 to 1.81) | |
| −3−2−1012Difference, per 100 births (linear scale) |
Original publication
Comparative Effectiveness and Safety of Labetalol Versus Nifedipine for Treatment of Chronic Hypertension During Pregnancy. JACC Adv. Published 7 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →